ReviewFrontiers in immunology2025
Harnessing the immunomodulatory properties of HLA-G for advanced immunotherapies.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- TMEM184A promotes progression and drug resistance in colorectal cancer: a bioinformatics and clinical study.Scientific reports · 2026Article
- Review
- Stromal resistance to placental invasion is a derived trait in ruminants.The Journal of reproduction and development · 2026Review
- Regulatory T cells in pregnancy disorders: a multi-dimensional framework for biomarkers and therapeutic strategies.Frontiers in immunology · 2026Review
- Integrated plasma proteomics identifies HLA-G and osteopontin as circulating biomarkers of resistance to PD-1 inhibitor plus chemotherapy in choriocarcinoma.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human leukocyte antigen-G (HLA-G) is a non-classical MHC class I molecule with unique immunomodulatory properties that extend far beyond its well-established role at the maternal-fetal interface. Increasing evidence highlights HLA-G as a pivotal regulator of immune homeostasis, capable of shaping both innate and adaptive cytotoxic responses. It exerts a context-dependent role, promoting tolerance in settings such as transplantation and autoimmunity while contributing to immune evasion in cancer and infection, and this functional plasticity is further shaped by its isoform diversity and its interplay with other non-classical HLA class I molecules. In this review, we discuss key aspects of HLA-G biology, particularly its capacity to promote immune tolerance or facilitate immune escape, and how these insights can be leveraged in the development of cellular and acellular immunotherapies. We further summarize current strategies that incorporate or target HLA-G in the treatment of malignancies and autoimmune diseases, and highlight its emerging potential as a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.